Cabometyx (cabozantinib)

pCPA File Number: 22491
Negotiation Status:
Active Negotiation
Indication(s):
Cabometyx in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC
Sponsor/Manufacturer:
Ipsen Biopharmaceuticals
CDA-AMC Project Number:
PC0312-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable